NEW YORK, Nov. 26 — GPC Biotech has signed an agreement to allow ICOS Corporation to develop and manufacture its anti-MHC class II antibody products, GPC said on Monday.
Terms of the arrangement call for ICOS, of Bothell, Wash., to conduct large-scale production of the two antibodies through a non-exclusive license to its mammalian cell-expression technology. GPC Biotech will retain rights to develop and commercialize the product.
Financial details of the deal were not disclosed.
GPC Biotech, a genomics and proteomics company based in Martinsried/Munich, Germany, identified these therapeutic antibody products with affinity for the MHC class II target through a research partnership with MorphoSys, also based in Martinsried/Munich.
One product is being developed as a potential treatment for certain types of B-cell lymphoma and the other may be an effective therapy for suppressing T-cell responses in the treatment of transplant rejection and graft-versus-host disease, GPC said. The antibodies were generated from MorphoSys' combinatorial antibody library.
Two weeks ago, GPC Biotech said that two new alliances have helped boost its third-quarter revenues by 65 percent to 3.5 million euros, or roughly $3.1 million, from 2.1 million euros in the year-ago period.
During the first nine months of the year, the company reported a 58 percent increase in research and development expenses to 23.4 million euros. GPC said that expenses from such activities totalled 14.8 million euros in the third quarter but did not offer a figure for the corresponding period in 2000.